Abstract
Atopic dermatitis (AD) is characterized by skin barrier dysfunction, for which the abnormal stratum corneum (sc) ceramide composition serves as one of the driving factors. Here, we assess effect of dupilumab on the regulation of skin barrier function and sc ceramide composition in patients with AD. BALISTAD (NCT04447417) was an open-label trial, in which Trans-epidermal Water Loss (TEWL) was assessed via skin tape strip (STS) samples from lesional skin of 26 patients with AD treated with dupilumab and from normal skin of 26 healthy volunteers over 16 weeks.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
